Currently, few studies have explored the role of VGLUT3 in PD, most studies focus on revealing the critical role of VGLUT3 in levodopa-induced dyskinesia (LID), which usually occurs in PD patients with long-term L-DOPA treatment (Divito et al., 2015; Gangarossa et al., 2016). This evidence concerns the gene SLC17A8 and Parkinson disease.